<?xml version='1.0' encoding='utf-8'?>
<document id="20091047"><sentence text="Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug."><entity charOffset="143-150" text="Calcium" /></sentence><sentence text="ACT-709478 is a selective, orally available T-type calcium channel blocker being studied as a potential new treatment in epilepsy"><entity charOffset="51-58" text="calcium" /></sentence><sentence text=" ACT-709478 had previously been investigated in a single-ascending dose study up to a dose of 400 mg" /><sentence text="" /><sentence text="The aim of this study was to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of ACT-709478" /><sentence text=" In addition, the drug-drug interaction potential of multiple doses of ACT-709478 with the cytochrome P450 3A4 substrate midazolam was investigated" /><sentence text="" /><sentence text="This double-blind, placebo-controlled, randomized study included 46 healthy male and female subjects" /><sentence text=" Ascending multiple oral doses of ACT-709478 were administered to 10 (cohorts 1-2) or 12 (cohorts 3-4) subjects (two taking placebo per cohort)" /><sentence text=" In cohorts 1-2, 30 or 10 mg ACT-709478 was administered once daily for 12 days" /><sentence text=" An up-titration regimen was used in cohorts 3-4 with administration of 10, 30, and 60 mg for 7 days each in both cohorts and an additional dose level of 100 mg ACT-709478 once daily for 8 days in cohort 4" /><sentence text=" Single doses of midazolam were administered at baseline and concomitantly to 60 mg and 100 mg ACT-709478 in cohort 4"><entity charOffset="17-26" text="midazolam" /></sentence><sentence text=" Blood sampling for pharmacokinetic evaluations and safety assessments (clinical laboratory, vital signs, adverse events, and electrocardiogram) were performed regularly" /><sentence text=" Holter electrocardiograms were recorded at baseline and for 24 h at steady state and central nervous system effects were assessed with pharmacodynamic tests at baseline and steady state" /><sentence text="" /><sentence text="ACT-709478 was absorbed with a time to reach the maximum plasma concentration of 3" /><sentence text="5-4" /><sentence text="0 h and eliminated with a half-life of 45-53 h" /><sentence text=" Steady state was reached after 5-7 days of dosing and exposure increased dose-proportionally" /><sentence text=" An accumulation index of approximately three fold was observed in cohorts 1 and 2" /><sentence text=" Exposure to midazolam was lower upon concomitant administration of 60 and 100 mg ACT-709478 compared to midazolam alone while the half-life and time to reach the maximum plasma concentration of midazolam remained unchanged, suggesting a weak induction at the gastrointestinal but not hepatic level"><entity charOffset="13-22" text="midazolam" /><entity charOffset="195-204" text="midazolam" /></sentence><sentence text=" Pharmacokinetic parameters of 1-hydroxymidazolam were not affected by ACT-709478 administration"><entity charOffset="31-49" text="1-hydroxymidazolam" /></sentence><sentence text=" The most frequent adverse events were dizziness, somnolence, and headache" /><sentence text=" A tolerability signal was detected in cohort 1 (30 mg once daily); therefore, the dose was decreased to 10 mg once daily in cohort 2" /><sentence text=" The subsequently established up-titration regimen, starting with 10 mg once daily, considerably improved tolerability" /><sentence text=" Multiple doses up to 100 mg once daily were well tolerated" /><sentence text=" No treatment-related effects were detected on vital signs, clinical laboratory tests, Holter electrocardiogram variables, or in the pharmacodynamic tests" /><sentence text="" /><sentence text="ACT-709478 exhibits good tolerability up to 100 mg once daily using an up-titration regimen and pharmacokinetic properties that support further clinical investigations" /><sentence text=" A weak induction of gastrointestinal cytochrome P450 3A4 activity was observed, unlikely to be of clinical relevance" /><sentence text=" CLINICALTRIALS" /><sentence text="" /><sentence text="NCT03165097" /><sentence text="" /></document>